Targeting the IL-15/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo
Vitiligo is a chronic autoimmune disorder in which melanocyte−specific CD8+ T cells destroy pigment−forming cells, producing persistent depigmented macules. Recurrence after treatment implicates tissue−resident memory T (TRM) cells that are maintained by interleukin−15 (IL−15) signaling. Here we rev...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1639732/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Vitiligo is a chronic autoimmune disorder in which melanocyte−specific CD8+ T cells destroy pigment−forming cells, producing persistent depigmented macules. Recurrence after treatment implicates tissue−resident memory T (TRM) cells that are maintained by interleukin−15 (IL−15) signaling. Here we review current insights into TRM−cell biology, summarize experimental and emerging clinical data targeting the IL−15/CD122 axis—including the ongoing Phase 2a AMG 714 trial—and discuss combination strategies with approved topical Janus kinase inhibitors such as ruxolitinib cream. Disrupting IL−15 may offer durable repigmentation with minimal systemic immunosuppression. |
|---|---|
| ISSN: | 1664-3224 |